Encompass More Asset Management Acquires 1,045 Shares of Natera, Inc. (NASDAQ:NTRA)

Encompass More Asset Management grew its stake in Natera, Inc. (NASDAQ:NTRA) by 45.6% during the 4th quarter, HoldingsChannel reports. The firm owned 3,337 shares of the medical research company’s stock after acquiring an additional 1,045 shares during the quarter. Encompass More Asset Management’s holdings in Natera were worth $528,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Donoghue Forlines LLC acquired a new stake in Natera in the 4th quarter valued at $2,024,000. Avior Wealth Management LLC increased its position in shares of Natera by 222.8% during the 4th quarter. Avior Wealth Management LLC now owns 3,412 shares of the medical research company’s stock worth $540,000 after purchasing an additional 2,355 shares in the last quarter. Wesbanco Bank Inc. bought a new position in Natera during the 4th quarter valued at about $317,000. Simon Quick Advisors LLC acquired a new position in Natera in the fourth quarter valued at about $246,000. Finally, Atomi Financial Group Inc. bought a new stake in Natera during the fourth quarter worth about $291,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Guggenheim boosted their target price on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Morgan Stanley increased their target price on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. StockNews.com cut Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Piper Sandler upped their price target on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. Finally, The Goldman Sachs Group raised their price objective on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $162.94.

Insider Activity

In other Natera news, insider Solomon Moshkevich sold 1,196 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $118.21, for a total transaction of $141,379.16. Following the sale, the insider now directly owns 110,695 shares in the company, valued at approximately $13,085,255.95. This trade represents a 1.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider John Fesko sold 669 shares of Natera stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $159.60, for a total transaction of $106,772.40. Following the completion of the transaction, the insider now directly owns 114,142 shares in the company, valued at approximately $18,217,063.20. The trade was a 0.58 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 224,133 shares of company stock worth $36,830,652 in the last 90 days. Corporate insiders own 7.60% of the company’s stock.

Natera Trading Up 0.2 %

NTRA opened at $172.11 on Friday. The firm’s fifty day moving average is $165.35 and its two-hundred day moving average is $135.41. The firm has a market cap of $22.72 billion, a PE ratio of -97.62 and a beta of 1.65. Natera, Inc. has a twelve month low of $62.96 and a twelve month high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same quarter last year, the business posted ($0.95) EPS. The firm’s revenue was up 63.9% compared to the same quarter last year. Equities research analysts anticipate that Natera, Inc. will post -1.56 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.